Haiming Kou

443 total citations
17 papers, 113 citations indexed

About

Haiming Kou is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Haiming Kou has authored 17 papers receiving a total of 113 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Hematology. Recurrent topics in Haiming Kou's work include CAR-T cell therapy research (11 papers), Blood properties and coagulation (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). Haiming Kou is often cited by papers focused on CAR-T cell therapy research (11 papers), Blood properties and coagulation (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). Haiming Kou collaborates with scholars based in China. Haiming Kou's co-authors include Heng Mei, Yu Hu, Mengyi Du, Chenggong Li, Cong Lu, Yinqiang Zhang, Wenjing Luo, Jun Deng, Huafang Wang and Tao Guo and has published in prestigious journals such as Blood, PLoS ONE and Frontiers in Immunology.

In The Last Decade

Haiming Kou

16 papers receiving 110 citations

Peers

Haiming Kou
Gary Douglas Myers United States
Sarah J. Albon United Kingdom
Nicole Verdun United States
Kevin O. McNerney United States
Sophia Bylsma United States
Sabine Tischer‐Zimmermann Germany
Karim El-Shakankery United Kingdom
Sarah J. Rockwood United States
Arina Lazareva United Kingdom
Alessandra Forcina Italy
Gary Douglas Myers United States
Haiming Kou
Citations per year, relative to Haiming Kou Haiming Kou (= 1×) peers Gary Douglas Myers

Countries citing papers authored by Haiming Kou

Since Specialization
Citations

This map shows the geographic impact of Haiming Kou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiming Kou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiming Kou more than expected).

Fields of papers citing papers by Haiming Kou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haiming Kou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiming Kou. The network helps show where Haiming Kou may publish in the future.

Co-authorship network of co-authors of Haiming Kou

This figure shows the co-authorship network connecting the top 25 collaborators of Haiming Kou. A scholar is included among the top collaborators of Haiming Kou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haiming Kou. Haiming Kou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Luo, Wenjing, Yinqiang Zhang, Chenggong Li, et al.. (2024). BTK Inhibitor Synergizes with CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients with Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial. Blood. 144(Supplement 1). 6546–6546. 1 indexed citations
3.
Kou, Haiming, Shuqin Jiang, Xinxin Xu, et al.. (2024). ZNF655 involved in the progression of multiple myeloma via the activation of AKT. Cell Biology International. 49(2). 177–187. 1 indexed citations
4.
Lu, Ping, Xinxin Xu, Cui Zhang, et al.. (2023). POLE2 knockdown suppresses lymphoma progression via downregulating Wnt/β-catenin signaling pathway. Molecular and Cellular Biochemistry. 479(3). 487–497. 1 indexed citations
5.
Luo, Wenjing, Chenggong Li, Yinqiang Zhang, et al.. (2023). P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA. HemaSphere. 7(S3). e4325339–e4325339. 1 indexed citations
6.
Luo, Wenjing, Chenggong Li, Yinqiang Zhang, et al.. (2022). Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. BMC Cancer. 22(1). 98–98. 35 indexed citations
7.
Du, Mengyi, Linlin Huang, Haiming Kou, et al.. (2022). Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma. Frontiers in Immunology. 13. 898341–898341. 6 indexed citations
8.
Zhang, Yinqiang, Fen Zhou, Yingnan Li, et al.. (2022). Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia. Frontiers in Immunology. 13. 914959–914959. 16 indexed citations
9.
Zhang, Yinqiang, Chenggong Li, Huiwen Jiang, et al.. (2022). Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies. Blood. 140(Supplement 1). 4592–4594. 4 indexed citations
10.
Mei, Heng, Lu Tang, Huan Zhang, et al.. (2022). Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies. Blood. 140(Supplement 1). 634–635. 2 indexed citations
11.
Du, Mengyi, Chenggong Li, Fen Zhou, et al.. (2022). Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL. Blood. 140(Supplement 1). 10321–10322. 1 indexed citations
12.
Du, Mengyi, Heng Mei, Chenggong Li, et al.. (2021). Single-Cell Analyses Identify Transcriptional Characterizations of Subsets Associated with Efficacy and Toxicity for CAR-T Immunotherapy in B-ALL Patients. Blood. 138(Supplement 1). 4815–4815. 1 indexed citations
13.
Li, Chenggong, Qi Chang, Jing Wang, et al.. (2021). Novel CD19-Specific γ/δ TCR-T Cells in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 138(Supplement 1). 826–826. 3 indexed citations
14.
Luo, Lili, Min Xu, Mengyi Du, et al.. (2020). Early coagulation tests predict risk stratification and prognosis of COVID-19. Aging. 12(16). 15918–15937. 17 indexed citations
15.
16.
Kou, Haiming, Jun Deng, Huafang Wang, et al.. (2015). Retrospective Evaluation of New Chinese Diagnostic Scoring System for Disseminated Intravascular Coagulation. PLoS ONE. 10(6). e0129170–e0129170. 19 indexed citations
17.
Mei, Heng, Haiming Kou, Jun Deng, et al.. (2015). Role of plasma high mobility group box-1 in disseminated intravascular coagulation with leukemia. Thrombosis Research. 136(2). 422–426. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gary Douglas Myers Breakdown of academic impact, for papers by Sarah J. Albon Breakdown of academic impact, for papers by Nicole Verdun Breakdown of academic impact, for papers by Kevin O. McNerney Breakdown of academic impact, for papers by Sophia Bylsma Breakdown of academic impact, for papers by Sabine Tischer‐Zimmermann Breakdown of academic impact, for papers by Karim El-Shakankery Breakdown of academic impact, for papers by Sarah J. Rockwood Breakdown of academic impact, for papers by Arina Lazareva Breakdown of academic impact, for papers by Alessandra Forcina
Rankless by CCL
2026